EP4720074A1 - Azines condensées utislisées en tant qu'inhibiteurs de tyk2 et leurs utilisations - Google Patents

Azines condensées utislisées en tant qu'inhibiteurs de tyk2 et leurs utilisations

Info

Publication number
EP4720074A1
EP4720074A1 EP24739674.0A EP24739674A EP4720074A1 EP 4720074 A1 EP4720074 A1 EP 4720074A1 EP 24739674 A EP24739674 A EP 24739674A EP 4720074 A1 EP4720074 A1 EP 4720074A1
Authority
EP
European Patent Office
Prior art keywords
substituted
unsubstituted
alkyl
fluoroalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24739674.0A
Other languages
German (de)
English (en)
Inventor
Anjali Pandey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sudo Biosciences Ltd
Original Assignee
Sudo Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sudo Biosciences Ltd filed Critical Sudo Biosciences Ltd
Publication of EP4720074A1 publication Critical patent/EP4720074A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés qui sont des inhibiteurs de TYK2, des procédés de fabrication de tels composés, des compositions pharmaceutiques et des médicaments comprenant de tels composés, ainsi que des procédés d'utilisation de tels composés dans le traitement d'états, de maladies ou de troubles qui bénéficieraient d'une modulation de l'activité TYK2. Formule (I).
EP24739674.0A 2023-05-26 2024-05-23 Azines condensées utislisées en tant qu'inhibiteurs de tyk2 et leurs utilisations Pending EP4720074A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363504693P 2023-05-26 2023-05-26
PCT/IB2024/000251 WO2024246599A1 (fr) 2023-05-26 2024-05-23 Azines condensées utislisées en tant qu'inhibiteurs de tyk2 et leurs utilisations

Publications (1)

Publication Number Publication Date
EP4720074A1 true EP4720074A1 (fr) 2026-04-08

Family

ID=91853738

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24739674.0A Pending EP4720074A1 (fr) 2023-05-26 2024-05-23 Azines condensées utislisées en tant qu'inhibiteurs de tyk2 et leurs utilisations

Country Status (9)

Country Link
EP (1) EP4720074A1 (fr)
KR (1) KR20260018891A (fr)
CN (1) CN121586716A (fr)
AR (1) AR132764A1 (fr)
AU (1) AU2024279507A1 (fr)
IL (1) IL324864A (fr)
MX (1) MX2025014163A (fr)
TW (1) TW202511266A (fr)
WO (1) WO2024246599A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4294806A1 (fr) 2021-02-19 2023-12-27 Sudo Biosciences Limited Inhibiteurs de tyk2 et leurs utilisations
TW202547473A (zh) * 2024-03-26 2025-12-16 美商Ｖ６醫療股份有限公司 選擇性ｊａｋ２抑制劑及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3208361A1 (fr) * 2021-02-19 2022-08-25 Anjali Pandey Inhibiteurs de tyk2 et leurs utilisations

Also Published As

Publication number Publication date
AU2024279507A1 (en) 2025-12-11
TW202511266A (zh) 2025-03-16
WO2024246599A1 (fr) 2024-12-05
CN121586716A (zh) 2026-02-27
AR132764A1 (es) 2025-07-30
KR20260018891A (ko) 2026-02-09
MX2025014163A (es) 2026-01-07
IL324864A (en) 2026-01-01

Similar Documents

Publication Publication Date Title
US12084458B2 (en) Substituted pyridines, pyridazines, and pyrimidines as TYK2 inhibitors
US12122785B2 (en) Substituted pyridines, pyridazines, pyrimidines, and 1,2,4-triazines as TYK2 inhibitors
WO2022175745A1 (fr) Inhibiteurs de tyk2 et leurs utilisations
US12600721B2 (en) TYK2 inhibitors and uses thereof
EP4720074A1 (fr) Azines condensées utislisées en tant qu'inhibiteurs de tyk2 et leurs utilisations
WO2023227946A1 (fr) Inhibiteurs de tyk2 et leurs utilisations
WO2024042361A1 (fr) Inhibiteurs de tyk2 et leurs utilisations
WO2025114761A1 (fr) Inhibiteurs de tyk2 et leurs utilisations
WO2025114760A1 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP4720064A1 (fr) Azolés fusionnés en tant qu'inhibiteurs de tyk2 et leurs utilisations
CA3208507A1 (fr) Inhibiteurs de tyk2 et leurs utilisations
CN117120440A (zh) Tyk2抑制剂及其用途
EA052784B1 (ru) Ингибиторы tyk2 и их применение
EA052918B1 (ru) Ингибиторы tyk2 и их применение
CN117242072A (zh) Tyk2抑制剂及其用途

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR